Submit Manuscript  

Article Details

Genetics in Anti-Platelet Treatment

[ Vol. 22 , Issue. 29 ]


Maria Gazouli   Pages 4506 - 4511 ( 6 )


Anti-platelet drugs are necessary in treating patients with coronary artery disease, ischemic stroke and peripheral arterial disease. However, despite the use of adequate anti-platelet therapy, some patients will experience a recurrent atherothrombotic vascular event. These patients are characterized as low- or non-responders to therapy. Individual responsiveness to anti-platelet therapy as the use of clopidogrel and/or aspirin varies widely among patients. Such an individual variability is mainly determined by environmental and genetic factors. In this review, we focused on the underlying genetic mechanisms that might influence response to anti-platelet drugs.


Anti-platelet therapy, aspirin, ticagrelor, prasugrel, clopidogrel, GPIIb/IIIa inhibitors, acute coronary syndromes, cardiovascular disease, gene polymorphisms, miRNAs.


Molecular Biology, Department of Basic Medical Science, Laboratory of Biology, Medical School, National and Kapodistrian University of Athens, Michalakopoulou 176, 11527 Athens, Greece.

Read Full-Text article